Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors.

Jacome Sanz, Dafne; Raivola, Juuli; Karvonen, Hanna; Arjama, Mariliina; Barker, Harlan; Murumägi, Astrid; Ungureanu, Daniela.

Afiliação

Jacome Sanz D; Laboratory of Immunoregulation, Faculty of Medicine and Health Technology, Tampere University, FI-33014 Tampere, Finland.
Raivola J; Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, FI-00014 Helsinki, Finland.
Karvonen H; Cancer Signaling, Faculty of Medicine and Health Technology, Tampere University, FI-33014 Tampere, Finland.
Arjama M; Institute for Molecular Medicine, FIMM, University of Helsinki, FI-00014 Helsinki, Finland.
Barker H; Clinical Medicine 5, Faculty of Medicine and Health Technology, Tampere University, FI-33014 Tampere, Finland.
Murumägi A; Fimlab Ltd., Tampere University Hospital, FI-33520 Tampere, Finland.
Ungureanu D; Institute for Molecular Medicine, FIMM, University of Helsinki, FI-00014 Helsinki, Finland.

Cancers (Basel) ; 13(15)2021 Jul 24.

Article em En | MEDLINE | ID: mdl-34359627